TICKERNERD
Menu
CORTCORTHealthcare · Biotechnology

CORT Stock Forecast: Corcept Therapeutics, Inc. Price Predictions for 2026-2027

Last close, 3 Aug 2026
$113
−1.48% on the day

The 4 Wall Street analysts covering Corcept Therapeutics, Inc. hold a median 12-month price target of $163 — +44.5% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 78 of 100 as at 1 Aug 2026 — inside the top quartile. Here, the model and the Street point the same way.

Market cap
$12.3B
Ticker Nerd rank
78 / 100
Median analyst target
$163
Analysts covering
4
Total return, dividends reinvested
1W
+23.8%
1M
+25.0%
YTD
+224.1%
1Y
+63.5%
From 52W high
−4.7%
From 52W low
+250.9%
$32
$118
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

CORT stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Corcept Therapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 1 Aug 2026
78 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Value
96
Revisions
92
Quality
85
Volatility
71
Momentum
60
Growth
48
Accruals
42
Issuance
42
Size
14

Value (96): The shares cost little relative to the profits and assets behind them — which can mean the market is too gloomy, or that the business really is in trouble.

Issuance (42): The company has been issuing shares or taking on financing, diluting existing holders.

Size (14): Larger than most of the companies we track — more scrutinised, less often mispriced.

The rank is the raw material. Whether the rules would actually own Corcept Therapeutics, Inc. — and when they’d sell — is the membership.

Wall Street

CORT stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on CORT, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$50$100$150Oct 25Jan 26Apr 26Jul 26CORTHigh $165Median $163Low $50

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

What Wall Street says4 analysts
3 Buy0 Hold1 Sell
Low $50Median $163High $165

The green dot is the last close — the median target sits +44.5% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 6 moved their price target up and 0 moved it down.

DateFirmActionRatingTarget
30 July 2026Canaccord GenuityMaintainsBuy$150 → $161
30 July 2026HC Wainwright & Co.MaintainsBuy$95 → $165
30 July 2026Piper SandlerReiteratesOverweight$88 → $165
29 July 2026Canaccord GenuityMaintainsBuy$135 → $150
27 July 2026Wolfe ResearchDowngradeUnderperform$50
28 May 2026Canaccord GenuityMaintainsBuy—
28 May 2026Canaccord GenuityMaintainsBuy$110 → $135
28 May 2026HC Wainwright & Co.MaintainsBuy$75 → $95
28 May 2026HC Wainwright & Co.MaintainsBuy—
13 May 2026UBSUpgradeBuy—
4 May 2026HC Wainwright & Co.MaintainsBuy—
1 May 2026Piper SandlerMaintainsOverweight—
26 Mar 2026Canaccord GenuityMaintainsBuy—
26 Mar 2026Wolfe ResearchUpgradePeer Perform—
25 Mar 2026HC Wainwright & Co.MaintainsBuy—
25 Feb 2026HC Wainwright & Co.MaintainsBuy—
20 Feb 2026HC Wainwright & Co.MaintainsBuy—
23 Jan 2026Canaccord GenuityMaintainsBuy—
23 Jan 2026HC Wainwright & Co.MaintainsBuy—
2 Jan 2026Canaccord GenuityMaintainsBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Estimates

CORT analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
EPS revision, 90 days
+37.1%
Analysts raising
2
Analysts cutting
1
Fundamentals

Corcept Therapeutics, Inc. (CORT) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
254.8×

Cheaper than 3% of US stocks

Price / sales
14.9×

Cheaper than 11% of US stocks

Price / book
17.5×

Cheaper than 6% of US stocks

EV / EBITDA
1494.0×

Cheaper than 1% of US stocks

Growth & margins
Revenue growth (YoY)
31.7%

Higher than 80% of US stocks

Earnings growth (YoY)
22.3%

Higher than 64% of US stocks

Gross margin
98.4%

Higher than 99% of US stocks

Operating margin
16.1%

Higher than 76% of US stocks

Net margin
6.6%

Higher than 64% of US stocks

Returns & dividend
Return on equity
8.2%

Higher than 60% of US stocks

Return on assets
0.5%

Higher than 46% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Peers

CORT vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
CORTCorcept Therapeutics, Inc.$12.3B
78
ARWRArrowhead Pharmaceuticals, Inc.$11.9B
63
BMRNBioMarin Pharmaceutical, Inc.$11.5B
70
TECHBio-Techne Corp.$11.2B
88
AXSMAxsome Therapeutics, Inc.$11.2B
74
EXELExelixis, Inc.$13.8B
97
MDGLMadrigal Pharmaceuticals, Inc.$10.7B
67
Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. CORT appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

News

Latest CORT news & analysis

Corcept Therapeutics: LIFYORLI Is Likely A Blockbuster, But The Valuation Already Knows It

Seeking Alpha · 31 July 2026neutral

LIFYORLI generated $47.6 million in its first full quarter, with management targeting $1 billion or more in U.S. peak revenue. However, the analyst notes that the strong launch and clinical demand are already reflected in Corcept's premium valuation, while non-LIFYORLI pipeline assets remain speculative.

Why it matters — A CORT watcher would care because the piece highlights that while LIFYORLI shows blockbuster potential, the stock's current valuation may already price in that success, and the rest of the pipeline is unproven.

CORT Q2 Earnings & Revenues Beat Estimates, 2026 Outlook Raised

Zacks Investment Research · 30 July 2026positive

Corcept Therapeutics reported Q2 earnings and revenues that beat estimates, driven by Korlym growth and a strong launch of Lifyorli. The company also raised its 2026 top-line outlook.

Why it matters — The raised 2026 outlook signals growing commercial momentum from both Korlym and the newly launched Lifyorli, key drivers of Corcept's near-term performance.

Corcept Therapeutics (CORT) Q2 Earnings and Revenues Surpass Estimates

Zacks Investment Research · 29 July 2026positive

Corcept Therapeutics reported Q2 earnings of $0.36 per share, beating the Zacks Consensus Estimate of a loss of $0.04 per share, and surpassing the $0.29 per share from the same quarter last year.

Why it matters — The company significantly exceeded analyst expectations, swinging from an anticipated loss to a profit that also topped its year-ago performance.

Corcept Therapeutics Q2 Earnings Call Highlights

MarketBeat · 29 July 2026positive

Corcept Therapeutics reported Q2 2026 revenue of $256.1 million, a 32% increase year-over-year, driven by its Cushing's syndrome franchise and $47.6 million from the first quarter of availability of its newly launched ovarian cancer therapy LIFYORLI.

Why it matters — The results show early commercial traction for LIFYORLI and continued growth in the core Cushing's syndrome business, making this an important update for investors tracking the company's product pipeline expansion.

FAQ

Frequently asked questions about CORT stock

What is the CORT stock price forecast for 2026-2027?

The 4 Wall Street analysts covering Corcept Therapeutics, Inc. have a median 12-month price target of $163, with estimates ranging from $50 to $165. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is CORT stock a buy right now?

Of the 4 analysts covering Corcept Therapeutics, Inc., 3 rate it a Buy, 0 a Hold and 1 a Sell. Ticker Nerd's systematic factor model ranks Corcept Therapeutics, Inc. 78 out of 100 across roughly 4,600 US stocks as at 1 Aug 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank CORT?

As at 1 Aug 2026, Corcept Therapeutics, Inc. ranks 78 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Value (96 of 100).

Will CORT stock go up?

No one can know that. What the data says: the median 12-month target from 4 analysts implies +44.5% from the last close, and Ticker Nerd's factor model ranks Corcept Therapeutics, Inc. 78 out of 100 as at 1 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the CORT stock forecast for 2030?

No analyst covering Corcept Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for CORT are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $50 to $165 over the next 12 months.

How has CORT stock performed over the past year?

Corcept Therapeutics, Inc. returned +63.5% over the 12 months to 3 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Corcept Therapeutics, Inc. do?

Corcept Therapeutics Incorporated is a commercial-stage pharmaceutical company focused on discovering, developing, and commercializing medications that address severe endocrine, metabolic, oncologic, and neurologic disorders. The company’s core scientific approach is based on modulating the effects of the hormone cortisol, which plays a central role in multiple disease pathways.

What is the latest news on CORT?

The most recent item we track (Seeking Alpha, 31 July 2026): "Corcept Therapeutics: LIFYORLI Is Likely A Blockbuster, But The Valuation Already Knows It". LIFYORLI generated $47.6 million in its first full quarter, with management targeting $1 billion or more in U.S. peak revenue. However, the analyst notes that the strong launch and clinical demand are already reflected in Corcept's premium valuation, while non-LIFYORLI pipeline assets remain speculative.

Company

About Corcept Therapeutics, Inc.

Corcept Therapeutics Incorporated is a commercial-stage pharmaceutical company focused on discovering, developing, and commercializing medications that address severe endocrine, metabolic, oncologic, and neurologic disorders. The company’s core scientific approach is based on modulating the effects of the hormone cortisol, which plays a central role in multiple disease pathways. Corcept Therapeutics today develops therapies for conditions such as hypercortisolism and is evaluating compounds in clinical settings for advanced ovarian and prostate cancers, amyotrophic lateral sclerosis (ALS), and metabolic dysfunction-associated steatohepatitis (MASH). Its portfolio is centered on proprietary cortisol modulators designed to offer targeted treatment options where existing therapies may be limited. Corcept Therapeutics markets its products primarily to healthcare providers and specialty treatment centers managing complex endocrine and oncologic conditions. Founded in 1998 and headquartered in Redwood City, California, the company operates within the broader health technology and major pharmaceuticals industry, contributing specialized expertise in cortisol biology to address serious, difficult-to-treat diseases.

CEO Dr. Joseph K. Belanoff M.D. · 730 employees · United States · https://www.corcept.com